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 Introduction 
 Scarce resources and limited funding opportunities re-
sulting from the global economic crisis are recently pos-
ing various challenges to research. Ethical conduct was 
anew in the spotlight, yet existing approaches to research 
ethics failed to frame these challenges so far. It is widely 
accepted that researchers have an obligation towards 
their fellow researchers in providing accurate and reliable 
research. Fabricating, misrepresenting or falsifying data 
not only reflects on the individual researcher or research 
group condoning these practices. It can influence results 
of other research and in the end infest policy and people’s 
lives. Holding on to norms like knowledge, truth, and 
avoidance of error are necessary conditions for reliable 
and trustworthy interpersonal collaboration and reflect 
the social responsibility inherent in research.
 Incidents, which highlighted in how far ethics is crucial 
in research, have been exemplified during events in the 
20th century, such as the Tuskegee study or research stud-
ies during the Nazi regime. Thereafter, the integrity of sci-
entists was considered to be of key importance. Since then, 
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 Abstract 
 Research ethics anew gained importance due to the chang-
ing scientific landscape and increasing demands and com-
petition in the academic field. These changes are further 
exaggerated because of scarce(r) resources in some coun-
tries on the one hand and advances in genomics on the oth-
er. In this paper, we will highlight the current challenges 
thereof to scientific integrity. To mark key developments in 
research ethics, we will distinguish between what we call 
research ethics 1.0 and research ethics 2.0. Whereas re-
search ethics 1.0 focuses on individual integrity and in-
formed consent, research ethics 2.0 entails social scientific 
integrity within a broader perspective of a research net-
work. This research network can be regarded as a network 
of responsibilities in which every stakeholder involved has 
to jointly meet the ethical challenges posed to research. 
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principles stated in the Belmont Report  [1] – respect for 
persons, beneficence, and justice – have been guiding prin-
ciples in research ethics ever since. The development of 
guidelines for research conduct and the evolution of in-
formed consent have also been described by Pelias  [2] . De-
velopments until this stage, which have been mainly deal-
ing with the relationship between researcher and research 
subject, is what we will refer to as research ethics 1.0.
 Recently, research ethics newly gained importance due 
to the changing scientific landscape and increasing de-
mands and competition in the academic field. Specifical-
ly in genomic research, a highly complex field both in 
terms of data complexity and privacy concerns, scientists’ 
integrity is key due to the fact that most sensitive data are 
involved and can impact the still hidden future of indi-
viduals, including the ones of future generations. How-
ever, we no longer can focus on the individual researcher 
or research group. The scientific process is embedded in 
a complex network with different stakeholders, which 
need to be more systematically addressed. Meslin and 
Cho  [3] analysed the existing “common set of ethical 
principles” in research ethics and proposed a reframing 
of the “social contract” between science and society, high-
lighting the need to put focus on the broader context of 
research. With this paper, we will extend the existing 
body of knowledge assessing the development or evolu-
tion of research ethics by highlighting the current chal-
lenges to scientific integrity. Thereby, to mark key devel-
opments in research ethics, we will distinguish between 
what we call research ethics 1.0 and research ethics 2.0. 
Whereas research ethics 1.0 focuses on individual integ-
rity and informed consent, research ethics 2.0 entails so-
cial scientific integrity within a broader perspective of a 
research network, as other actors apart from researcher 
and research subject increasingly move into the core of 
research ethics. The aim of this paper is thus to inform in 
a comprehensive way about recent challenges to research 
ethics which become evident through our so-called “re-
search network” perspective. In this way, the research 
network serves as a framework through which changes 
and complexities in research ethics are modelled and can 
be systematically conceived.
 Research Ethics 1.0: Focussing “Informed Consent” 
 A basic moral conflict in research ethics is balancing 
between the good for the individual and the good for the 
population. Certain medically oriented research ques-
tions that ultimately aim to benefit the population or fu-
ture generations of patients can only be answered by in-
volving individuals. Depending on the intervention, drug 
or placebo under research, those individuals however can 
be part of studies with uncertain outcomes. Two historic 
medical studies that failed to adhere to ethical standards 
exemplify the severe consequences. Even though nearly 
every public health lecture and textbook in the Western 
world mentions these studies and their misconduct is 
commonly known, they illustrate what constituted re-
search ethics during the twentieth century. In these ex-
amples of scientific misconduct, research subjects were 
treated not as ends in themselves but were harmed for the 
benefit of others, while not being adequately (or not at all) 
informed about the nature of the research or pressured to 
participate.
 The Tuskegee study, which was initiated by the US 
Public Health Service in 1932 aimed at revealing conse-
quences of untreated syphilis  [2] . Four hundred already 
infected Afro-Americans from Tuskegee, AL, were stud-
ied over a period of 4 decades (from 1932 until 1973) 
through a purely observational study even when effective 
penicillin treatment became available, yet subjects were 
not even informed about it. Treatment was only offered 
to the subjects when the study was publicly exposed in 
1973  [4, 5] .
 The other example that influenced the awareness of 
the rights of human research subjects in research is the 
study carried out at Willowbrook State School, New York, 
from 1956 until 1971, which intended to find a cure for 
infectious hepatitis. The school for “ mentally  retarded” 
children admitted new pupils only after their parents con-
sented to place them in the hepatitis unit, where they were 
actively infected with the virus in order to “determine a 
prophylactic agent”  [2, 6] .
 It was through events like these that ground was given 
for ethical questions in relation to research and protect-
ing study subjects. Responses to such immoral studies 
have emerged since the biomedical experiments during 
the Nazi regime. It turned out that although in Nazi Ger-
many, rules for the protection of human research subjects 
already existed, they were violated by Nazi doctors in 
their “research”  [7] . In response to the misconduct, the 
Nuremberg Code was set forth during “The Nazi Doctors 
Trial” in 1947 and aimed to proclaim 6 norms for protect-
ing research subjects (Box 1). The Nuremburg Code can 
hence be deemed as the “foundation of modern protec-
tion of human rights” [ 2 , p. 74].
 In 1964, the World Medical Association established 
the Declaration of Helsinki and regularly updated it ever 
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ing human subjects. It was a further elaboration of the 
Nuremberg Code, paying attention to the distinction be-
tween therapeutic and non-therapeutic research and re-
sponsibility towards vulnerable groups  [8] . The Belmont 
Report issued by the US National Commission for the 
Protection of Human Subjects of Biomedical and Behav-
ioural Research in 1978 also served as a basis for several 
other codes of ethics through its three principles. While 
respect for persons emphasises absolute autonomy of re-
search subjects, beneficence seeks to safeguard the mini-
misation of risks. Justice stresses the importance of dis-
tributing chances and risks of research fairly and treating 
subjects in a just way. These principles are also in line with 
the four principles of biomedical ethics proposed by 
Beauchamp and Childress  [9] in 1977 which have offered 
an influential normative framework ever since.
 Research Ethics 2.0: New Perspectives on Norms, 
Values, and Integrity 
 While research ethics during the 20th century was 
characterised by questioning behaviour mainly in the re-
lationship between researcher and research subject, the 
21st century brought to the forefront further issues at 
stake that go beyond this bilateral relationship. They en-
compass multiple levels, and have diverse underlying in-
fluencing causes and reasons. Even though these “new” 
issues might have existed before, they become more and 
more important due to increased interdependence be-
tween the stakeholders. In what follows, we will describe 
these multiple levels and challenges for various stake-
holders, in what we are calling research ethics 2.0. Instead 
of focusing only on the relationship between researcher 
and research subject, research ethics 2.0 takes into ac-
count the broader social dimension of research that we 
depict as a research network, which we could also term 
“network of responsibilities” as different relations of 
moral responsibilities of the researcher(s) with other 
stakeholders and actors play a role ( Fig. 1 ). Identification 
of the stakeholders was based on a literature review fol-
lowed by a grouping of the key stakeholders involved in 
the research realm. Even though we offer a researcher-
centrist view of the network, the relationships and mu-
tual responsibilities between other actors also play an in-
fluential role.
 At the heart of the research process lies the researcher 
who is influenced by several stakeholders and factors. Ac-
ademic competition poses pressure on researchers. Fund-
ing opportunities, prestige, and recognition are often de-
pendent on the number of articles published, the magni-
tude of studies conducted, and the amount of high-profile 
journals published in. The difficulty to win research funds 
is even more exacerbated in times of austerity, while pub-
lishing higher numbers of papers to gain doctoral degrees 
and/or to have research careers might lead to arguable 
incentives for non-accurate research or even wasted re-
search efforts. All these situations pose a challenge to re-
searchers’ scientific integrity. According to the Swiss 
Academy of Medical Sciences  [10] , scientific integrity can 
be termed as “the voluntary commitment by researchers 
to comply with the basic rules of good scientific practice: 










 Fig. 1. The research network as a network of responsibilities. 
 Box 1.  The Nuremberg Code 1947 [2]
1 Human subjects must give voluntary, informed consent, 
without coercion or duress
2 Experiments with human subjects should be preceded by 
experiments with animals
3 Experiments should be justified by the anticipated results
4 Experiments should be conducted by qualified scientists
5 Experiments should avoid physical and mental suffering 
and injury
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ally correct behaviour.” However, researchers are pres-
sured to achieve those stated requirements, not lastly by 
conducting so-called “scientific misconduct,” which is 
defined as “fabrication, falsification, or plagiarism (FFP) 
in proposing, performing, or reviewing research, or in re-
porting research results”  [11] . According to Bouter [ 12 , 
p. 150], many variances of misconduct or “questionable 
research practices” emerged in the grey zone between car-
rying out research according to the rules and three latter 
new “deadly sins” for scientific integrity (FFP). He states 
that the reasons for such behaviour can, in the best case, 
simply be unawareness of how it should be done or, in the 
worst case, that researchers know about the wrongdoing 
involved but proceed in those practices anyway for vari-
ous reasons. Martinson et al.  [13] argue that from an em-
pirical study about US researchers’ behaviour in terms of 
integrity, commonplace unfavourable research practices 
are a bigger threat to science than those produced by 
“high-profile misconduct cases such as fraud” (p. 737). 
Their survey of more than 3,000 early- and mid-career 
researchers in the US about ten common and six other 
research behaviours that were previously determined in 
focus group discussions reveal that 33% of respondents 
acknowledged to have conducted at least one of those be-
haviours, which range from falsifying, polishing or “cook-
ing” research data to using the ideas of others without 
obtaining permission or giving credit to changing the de-
sign or results of the study due to funding source pres-
sures. Other questionable research practices of the grey 
zone include refraining from publishing disappointing 
study results, publishing the same data in several publica-
tions, withholding results in line with selective reporting 
or other details or using inadequate research designs.
 Behaviours, which are affected by social structures, are 
also important to take into account. Those behaviours in-
clude authorship questions, such as who can or should be 
author or the promotion of young scientists or lack there-
of  [14] . Lack of self-criticism of scientists on the one hand 
and dealing with multiple obligations, which can be over-
whelming, on the other hand – including promoting 
young academics, acquiring funding, engaging in review 
and university boards, publishing, and teaching – further 
facilitate misconduct when accuracy in every task cannot 
be accomplished. Additionally, questions about justly 
dealing with research resources emerge, not only since 
the economic crisis, which will further be touched upon 
in the paragraph concerning funders hereinafter.
 Martinson et al.  [13] rightfully claim that current anal-
yses only focus on researchers and their misconduct but 
fail to consider the broader research environment, in-
volving its structures, which often trigger the researchers’ 
misconduct through what Bouter  [12] and Sandel  [15] for 
instance call “perverse incentives.”
 Taking the broader research environment into consid-
eration extends the focus to the research network. In the 
researcher-centric network of responsibility, we see the 
following actors and stakeholders ( Fig. 1 ). The researcher 
is connected to all of the different stakeholders. Even 
though the research environment is vast and complex, we 
identify 6 other stakeholders besides the researcher: re-
search subjects, colleagues, editors/publishers, profession-
al associations, universities, funders, and society at large. 
 The classic – and already mentioned above – relation 
to the research subject focuses on questions around 
avoiding harm and properly informing the research sub-
ject. Especially in the context of genomic research, big 
data, and digitalisation, new challenges continuously 
arise, such as aspects of the right not to know, data pro-
tection, and privacy, all of which have to be imbedded in 
the considerations for informed consent. Current re-
search, as for example, advances in gene editing, is mov-
ing the frontiers of impacting only the single research 
subject but extends gained knowledge and its conse-
quences to genetically related persons and thus future 
generations. Here, existing and traditional models of in-
formed consent, such as opt-out, waiver, no consent, and 
open or categorical consent, need to be revised in order 
to meet the challenges posed. Incidental findings of ge-
nomic data, e.g. predisposition for diseases, furthermore 
pose a challenge as to how to deal with this information 
with regard to truthfulness and individual autonomy. 
With regard to also protecting privacy of biological rela-
tives existing models should be further revised.
 It is furthermore important to focus on aspects of non-
exploitation of research subjects. Especially in times of 
austerity, non-exploitation becomes relevant in studies 
where people become research subjects on the basis of the 
incentives – often of financial nature – that they receive 
 [16] . Generating research subjects at costs of potentially 
adverse side effects of the respective study is morally un-
justifiable, not only since the Tuskegee experiments and 
the Declaration of Helsinki. Some forms of exploitation 
continue to occur, often in low-income countries  [17] . It 
is well established that in poor settings, such as under-
served communities and countries, inequitable access to 
resources have an important role to play in people’s deci-
sions to partake in research  [18, 19] and that in resource-
poor settings, voluntary informed consent is undermined 
by financial incentives  [16] . Partaking in research can also 
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sion when otherwise health care services are not readily 
accessible. This would be the case of early accessible and 
usually costly genomic treatment during research studies, 
where research subjects are often patients who wish to ac-
cess and aim to benefit from evolving treatments  [20] .
 However, according to Chalmers and Glasziou  [21] 
there is often a mismatch between the research questions 
and the expected outcome for patients. Data are more-
over available too late, with an average of nine years later 
 [21] . It must hence be a researcher’s responsibility to en-
sure timely and unbiased publication of study findings 
and a matching of research questions and patients’ expec-
tations  [21] . When these requirements are not guaran-
teed, the already vast amount of unused research – which 
is deemed to account for 85%  [21] – is “waste.”
 In addition to research subjects, the researcher is re-
lated to his/her circle of colleagues, both from the aca-
demic environment as well as collaborators from other 
institutions at public and private levels. Here, it is impor-
tant that the relation is defined through ethical principles 
of the professional roles, such as honesty in sharing study 
results or newly developed concepts and trust that the in-
formation is not used without permission or adequate 
credit. Also sharing confidential information, e.g. about 
participants who should stay anonymous, or failing to 
store study data securely, so that colleagues can access raw 
material remain questionable, as the moral duty towards 
research subjects to expose information only to partici-
pating researchers is undermined. 
 During the focus group discussions in the study by 
Martinson et al.  [13] , a concern was also raised about 
questionable relationships with students, research sub-
jects, or clients. Concerning the former, the ethical con-
cern about questions of authorship is central. While at 
least in Germany, it used to be (and is still the case in some 
disciplines) that students’ theses are published without 
their name in the author list, it also often is the opposite 
case, namely that colleagues who want to accelerate their 
career or PhD students are authors on various publica-
tions to which they have contributed little or nothing at 
all. This practice can be seen as undermining competition 
and thus has to be regarded as unfair.
 On another similar note, peer review – according to 
Bouter  [12] the dominant kind of quality assessment – of-
ten affects or is affected by the relationship between col-
leagues. When assessing research proposals or manu-
scripts, objectivity is rather problematic. In some biomed-
ical or niche disciplines, colleagues’ works can be identified 
even when manuscripts are submitted anonymously. Re-
jecting manuscripts of competitors, or punishing col-
leagues who reviewers are in dispute with could be an easy, 
yet untruthful and mendacious way to increase one’s own 
research career  [22] . Lawrence  [22] even reports from his 
experience as editor, that half of all submissions he re-
ceived asks for not sending the submission to certain re-
viewers due to “conflicts of interest” and fear that confi-
dential data and ideas are misused. Lawrence, however, 
purports that this could be a fruitful way to circumvent 
especially critical or unfavourable reviewers. Reviewer ac-
tivities for different journals can pose an even higher 
workload to scientists that is not recognised or valued as 
part of their research or faculty-related work. Whether the 
evaluation process of a reviewer should be recognised and 
in which ways this could be operationalised needs to be 
assessed and possible options are to be discussed. Trans-
parency, anonymity, and disclosure issues are central is-
sues to be taken into account therein  [23] .
 Sharing study results and methods is another issue 
pertaining to the relationship with colleagues, which 
gains increasing attention with advances in genomic re-
search. By improving sharing behaviours between col-
leagues, research waste can be reduced to an enormous 
extent, as already existing data and methods can be used 
and applied respectively  [24] . New research can then refer 
to and use existent knowledge instead of duplicating re-
search in new settings.
 The quest for seeking the “right” reviewers is an issue 
which editors have to deal with daily, and which leads us 
to the next stakeholder in the network of responsibilities: 
the editors or publishers. For researchers, there is often a 
bias towards publishing in popular journals, as the prob-
ability of getting cited is deemed to be higher and impact 
factors count for their careers. That this system is mor-
ally questionable is discernible and leads to a domination 
of certain journals, whereas more unknown journals can-
not compete. An unfair competition for researchers is 
recognisable in the long journey of publication, which 
can vary as long as several years from submission to ac-
tual publication depending on reviewers’ availability and 
promptitude and editors’ decisions whether to publish or 
not and in which volume of their journal. English natives 
also have a competitive advantage, since most journals 
publish in English, posing a barrier to scientists from oth-
er language-speaking countries. The responsibility of ed-
itors and publishers for ensuring progress in research is 
central, as they can most often decide what type of re-
search papers get commissioned and published or not – 
and thereby receives a platform for further communica-
tion and discussion or not. Here, publication of negative 
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cessful” and interesting research to be published, but 
which nevertheless promotes knowledge and provides 
other researchers with information about which scien-
tific approaches or experiments are not fruitful.
 Editors and publishers have the power to put topics 
and theses on the agenda and hence shape not only the 
academic context to a great deal, but also society as a 
whole. The failure to focus on promising topics, however, 
also has an impact. Their role can be termed as being re-
sponsible towards society in shaping or pushing the re-
search agenda into the “right” direction. They also have 
responsibility towards research subjects, which they en-
sure by checking granted research ethics approvals. How-
ever, many publishers and editors also come under pres-
sure – or a “crisis” of publishing as Richard Horton  [25] 
of  The  Lancet describes it. They experience a paradigm 
shift from a focus on quality of publications rather to 
quantity of publications issued by journals. With the 
emergence of so-called mega journals, which publish ap-
proximately 30,000 articles a year, other motives rather 
than scientific excellence are emphasised. These motives 
relate more to a high market share and connected bene-
fits, such as “revenue growth, cost control, and profitabil-
ity” [ 25 , p. 322], even more so in times of economic hard-
ship. For publishers and editors who used to function as 
gatekeepers to scientific publications, which should be 
based on excellence, this change has affected their core 
values and decisions pertaining to what is deemed science 
and relevant research. Moral questions about the purpose 
of scientific publications arise, reflecting or indicating a 
change in publishers’ values. Instead of only focusing on 
volume and market share, Horton sees it as publishers’ 
responsibility to focus on the added value of science to 
society. Hence, publishers’ integrity to not only engage in 
profitability is key in developing science in a time where 
big datasets would easily provide substance for all sorts of 
publications. The question however, remains whether 
gatekeeping research for publication with the aim to pub-
lish only high quality research adversely affects transpar-
ency. Finding the right balance in this regard will remain 
a challenge and key in the years to come.
 Professional communities are often organised in pro-
fessional associations – another stakeholder in the net-
work of responsibilities. Professional associations pool 
their members’ scientific experience and knowledge and 
can hence be intellectually supportive for their members. 
A prime responsibility professional associations should 
take on is the development of guidelines for conducting 
research or establishing links between researchers to 
strengthen research for example. Yet, promoting interna-
tional collaborations in forms of scholarships or travel 
grants might get more difficult for professional associa-
tions, as their budgets in some cases were reduced in the 
last years due to unpaid membership fees. By steering the 
research of their scientific community in the direction 
they deem promising, professional associations take on a 
leadership role. However, as in every community, chal-
lenges can emerge with regard to internal power strug-
gles, personal discrepancies or different values. Hence, 
defining a common value set can help to align motives 
and avoid conflicts of interest. In addition to interdepen-
dencies as well as responsibilities towards colleagues, pro-
fessional associations are accountable to society, and can 
and should aim to promote added value of their research 
activities.
 Also universities, as institutional organisations within 
the research network, prescribe to the aim to promote 
added value to research. Their role as institutions is to 
provide safe working spaces and fruitful working envi-
ronments for both researchers and their study results by 
securing proper storage of data, upholding anonymity of 
research subjects and providing the necessary infrastruc-
ture to support research endeavours. In light of scarce 
resources, buying new technology or renewing existing 
buildings or offices remains challenging. Prioritising 
what to invest in should be evaluated fairly and objec-
tively so that standards are upheld and all departments 
within a university are equitably treated. With regard to 
meeting the obligation or legal requirement to regulate 
research by assessing ethical implications of research, in-
stitutional review boards have to be established and re-
search ethics training should be institutionalised. More-
over, universities often set incentives for research, which 
however have to be arranged in a fair way.
 Funders have a crucial role within the network of re-
sponsibilities, as research is in nearly all cases dependent 
on the funding agencies involved. These funding agencies 
or stakeholders can vary widely and can be embodied by 
stakeholders either from the public sphere such as gov-
ernment, advocacy groups or non-governmental, non-
profit organisations; or can stem from private corpora-
tions with industry being the most ostensible. Various 
moral obligations are involved for each stakeholder, for 
example with regard to being accountable to where fund-
ing is from and for which purpose it is offered. Academics 
who are in advisory boards of industrial companies can 
easily get into conflicts of interests, which can result in 
exploiting either industry or university resources or peo-
ple working there  [26] . Governmental funding for an in-
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morally questionable in terms of justice when research is 
publicly funded. However, as austerity measures heavily 
affect governmental budgets for research and develop-
ment since 2008, private funding becomes more and 
more important and can yield new funding schemes, such 
as mutual funds or research bonds as proposed by Moses 
and Dorsey  [27] . Evidence exists that austerity measures 
have negatively affected not only pharmaceutical growth 
 [28] but that publicly funded independent clinical trials 
could not be carried out as funds were not disbursed since 
2012 such as was the case in Italy  [29] . The scheme from 
which funding was generated was based on a newly raised 
5% tax on pharmaceutical marketing, established in 2005. 
This type of revenue for funding can be regarded as being 
a fair measure to balance excess profits from the pharma-
ceutical field to usually underfunded public or indepen-
dent research. Funders have to respond to political inter-
ests or even “hypes” in certain research fields, for which 
the demand for distributing grants is strong. Acting on 
this demand can create inequalities between different 
fields of study  [30] . Fewer funding opportunities have led 
to increased competition with regard to EU grants. Spe-
cifically for resource-poor countries, EU grants are often 
an essential possibility to fund research and maintain re-
search infrastructure, e.g. in EU member states that were 
hit hard by the economic crisis. Along the same lines, 
continuing low levels of funding will create more uncer-
tainty for young researchers, who would rather search for 
a career in other, mostly private, sectors.
 Here, the question arises whether the liberal approach 
of providing grants based on competition is still justifi-
able in times of austerity or whether mechanisms that put 
a bigger focus on solidarity should be installed. In short, 
low levels of funding have adverse consequences for soci-
ety in general as biomedical or genomic research yields 
prosperity and other economic benefits by creating jobs 
and valuable products and methods  [3, 27] .
 Even if funds are available, further issues arise with re-
gard to the already mentioned vast amount of 85% waste 
in research  [21] , such as whether it is ethically justifiable 
to fund research which cannot be translated into practice 
or which aims to answer irrelevant or already answered 
research questions. The open science movement raises 
novel questions as to how to deal with raw data and study 
results funded by public resources. There are arguments 
for sharing data publicly and making them available 
through open access, which promotes access and thus 
freedoms to lay persons, as well as arguments questioning 
whether such access might result in misuse or misinter-
pretation of data. A thorough discussion of this issue 
however, goes beyond the scope of this paper. The role of 
funders, in collaboration with other stakeholders, such as 
researchers, universities, and society, is crucial in order to 
define common standards for funding practices.
 With regard to society – our last stakeholder – new 
challenges have to be met in times where amounts of data 
increase rapidly and funding for research is scarce. Soci-
ety’s role in research increased in the last years due to the 
fact that advocacy groups, e.g. patient advocacy groups, 
and community engagement actions were paid more re-
gard to in defining research priorities on the political lev-
el  [31] . By this engagement, societal values became part 
of the scientific undertaking. Resnik argues that even 
though science is deemed objective, evidence-based, and 
“value-free,” it nevertheless involves researchers’ epis-
temic and non-epistemic values  [32] . Being aware and 
transparent about those values is central to improving the 
perception of science in society and strengthening their 
link. According to Meslin and Cho  [3] , research during 
the era of personalised medicine needs an update on what 
they call “social contract between science and society.” 
Hitherto, research was based on the precautionary prin-
ciple as well as non-maleficence and protectionism, which 
all resulted in a request for more regulation and require-
ments of researchers and delineates a lack of trust in the 
latter. This lack of trust is also noticeable in the unsteady 
support to scientists by society, when support comes eas-
ily if results are progressive, but can be withdrawn rap-
idly when researchers are deemed to be driven by per-
sonal or industry-related motives  [3] . Due to the chang-
ing landscape in research following novelties in genomic 
understanding and big data availability, such lack of trust 
can hinder advances tremendously. Therefore, a new 
framework has to be established, which should still root 
in avoiding harm, but moreover provides scientists with 
the necessary trust to conduct research freely, however 
with the best interest for society’s needs and values. 
Hence, the social contract between scientists and society 
is increasingly based on integrity of scientists. Meslin and 
Cho propose within their “recipe for reciprocity” four 
ways by which researchers can confirm their integrity to 
society, namely by “(1) a clear articulation of goals and 
visions of what constitutes benefit, without overstate-
ment of benefit, (2) a commitment to achieving these 
goals over the pursuit of individual interests, (3) greater 
transparency, and (4) involvement of the public in the 
scientific process” [ 3 , p. 379]. Society would return con-
sequently “(1) trust in the process and goals of science, (2) 
a greater willingness to volunteer to participate in re-
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greater academic freedom, free from manipulation by po-
litical goals or ideology” [ 3 , p. 379].
 Besides emphasising values or principles for research-
ers to act upon, Meslin and Cho propose an increased 
inclusion of society in science. Citizen Science – as a rela-
tively new term describing a rather old approach – in-
cludes laypersons as volunteers in research projects, e.g. 
in data collection, recruitment of research subjects or 
communicating results to society. Advantages include 
besides assistance in data collection, an improved insight 
for volunteers into science and scientific methods, and 
the possibility to engage in issues, which are relevant to 
them and their environment  [33] . Ethical considerations 
emerge however, with regard to data integrity and shar-
ing, intellectual property and authorship rights, respon-
sible oversight and training of volunteers, and exploita-
tion  [34] .
 As regards scientists, strengthening their commitment 
to public benefit will contribute to their integrity and lead 
to valuable relationships, which have a greater potential 
to meet society’s needs.
 Concluding Remarks 
 Research practice and the researchers’ environment 
have changed in the last years – economic pressure in 
times of austerity and genomic advances can be seen as 
two drivers for research ethics 2.0. The network of re-
sponsibilities described above shows the many (more) 
ethical issues researchers and other stakeholders or actors 
have to face nowadays. The integrity of research – imply-
ing adherence “to the basic rules of good scientific prac-
tice (such as) honesty and sincerity, self-discipline, self-
criticism, and fairness”  [10] – is challenged on diverse 
levels. Our claim is that focusing on research ethics and 
integrity on those various levels and taking into account 
all stakeholders can make research better, more truthful 
and thereby more socially acceptable. It is important that 
research is socially acceptable since it influences support 
for research in general. As Gunn has already pointed out 
in his Editorial in 1917, scientific misconduct, waste, or 
sloppy methods can undermine the integrity of “the 
whole public health movement” and have a negative im-
pact on human welfare  [35] . Even though this statement 
has been made a century ago, it has not changed ever since 
but is even more crucial with regard to genomic research.
 In some cases, integrity might hinder research, for in-
stance when conflicts of interest supersede funding, in 
others it promotes research, e.g. when professional asso-
ciations engage in research collaborations. However, ap-
plying ethics and moral values enhances research and as 
such is not only a means to an end but also a necessary 
end in itself. Moral values can thus be regarded as drivers 
for science as they provide accountability and public trust 
to society and vice versa. What is new with regard to the 
mentioned recent challenges is that research ethics can-
not focus on the relationship between researcher and sub-
ject alone anymore  [36] . All stakeholders within the 
broader research field build a  network of mutual respon-
sibilities, rights, and duties.
 It is crucial to strengthen integrity in the years to come. 
An auspicious way to do this is by means of education. 
Bouter  [12] suggests that education and training about sci-
entific integrity for PhD students as well as for permanent 
academic staff should be implemented. This could not 
only be done by lectures, but more profoundly and accord-
ing to successful didactic methods such as group work and 
case studies  [37] . Moreover, existing policies are to be re-
framed on the basis of the established network of respon-
sibilities in order to provide improved guidance for the 
various stakeholders involved, e.g. to better protect re-
search subjects or involve volunteers by means of citizen 
science, especially for research in times of scarce resources. 
 The field of research ethics however is still developing, 
and more and more aspects of research collaboration are 
being discussed. Therefore, there is still a magnitude of 
issues undiscovered. The account provided in this paper 
thus does not aim to be comprehensive, but to provide a 
heuristic endeavour to involve all stakeholders concerned 
within a network approach. It extends the classic bilat-
eral relationship between researcher and research sub-
jects towards the network of responsibilities and aims to 
specify some challenges at hand. Due to the multitude of 
developments ahead, a continued discussion is needed in 
which ways ethic(ist)s can support research. Central top-
ics and challenges in genomic research where further eth-
ical assessment is needed include the issue of data sharing 
and making use of existing data, open science concepts, 
and the role of science in the age of digitalisation.
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